ArticleFrontiers in oncology2025
Multimodal ultrasonography for predicting epidermal growth factor receptor mutation in subpleural non-small cell lung carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Currently precise target treatment based on gene status significantly improved the outcome for patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) was the most important gene. We aimed to develop a multimodal ultrasound model for predicting EGFR mutation status in patients with subpleural NSCLC, to provide important information for precise target treatment. Methods: 75 patients with pathologically confirmed NSCLC were included in this retrospective study. Patients were divided into two groups based on EGFR mutation status: wild-type (n=57) and mutant (n=18). The clinical characteristics (C), conventional ultrasound (US) features, contrast-enhanced ultrasound (CEUS) characteristics, and time-intensity curve (TIC) parameters of the lung lesions were analyzed and compared between the two groups. Univariate and multivariate logistic regression determined independent predictors of EGFR mutations. Two predictive models were constructed: a C+ US model and a FULL model. Both were presented using nomograms. Receiver operating characteristic and calibration curves evaluated predictive performance of two models, while decision curve analysis (DCA) assessed clinical utility. Results: Multivariate analysis identified smoking status, lesion boundaries, and air bronchogram as predictors in the C + US model. The FULL model identified lesion boundaries and air bronchogram on US, enhancement intensity of lesions and internal necrosis on CEUS and RT (rise time) from TIC as predictors. The C + US model achieved an AUC of 0.843, and the FULL model achieved 0.939. DCA confirmed substantial net clinical benefits. Conclusion: The models developed in this study enabled patients who are unable to undergo invasive procedures to predict EGFR mutation status noninvasively. These findings provided an ultrasound-based diagnostic reference to support clinician decision-making and personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.